Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jan 29;98(2):282-8.
doi: 10.1038/sj.bjc.6604170. Epub 2008 Jan 22.

Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis

C L Pearce  1 , A H Wu, S A Gayther, A E Bale; Australian Cancer Study (Ovarian Cancer) and Australian Cancer Study Group; P A Beck, J Beesley, S Chanock, D W Cramer, R DiCioccio, R Edwards, Z S Fredericksen, M Garcia-Closas, E L Goode, A C Green, L C Hartmann, E Hogdall, S K Kjaer, J Lissowska, V McGuire, F Modugno, K Moysich, R B Ness, S J Ramus, H A Risch, T A Sellers, H Song, D O Stram, K L Terry, P M Webb, D C Whiteman, A S Whittemore, W Zheng, P D P Pharoah, G Chenevix-Trench, M C Pike, J Schildkraut, A Berchuck; Ovarian Cancer Association Consortium
Affiliations

Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis

C L Pearce et al. Br J Cancer. .

Abstract

There is evidence that progesterone plays a role in the aetiology of invasive epithelial ovarian cancer. Therefore, genes involved in pathways that regulate progesterone may be candidates for susceptibility to this disease. Previous studies have suggested that genetic variants in the progesterone receptor gene (PGR) may be associated with ovarian cancer risk, although results have been inconsistent. We have established an international consortium to pool resources and data from many ovarian cancer case-control studies in an effort to identify variants that influence risk. In this study, three PGR single nucleotide polymorphisms (SNPs), for which previous data have suggested they affect ovarian cancer risk, were examined. These were +331 C/T (rs10895068), PROGINS (rs1042838), and a 3' variant (rs608995). A total of 4788 ovarian cancer cases and 7614 controls from 12 case-control studies were included in this analysis. Unconditional logistic regression was used to model the association between each SNP and ovarian cancer risk and two-sided P-values are reported. Overall, risk of ovarian cancer was not associated with any of the three variants studied. However, in histopathological subtype analyses, we found a statistically significant association between risk of endometrioid ovarian cancer and the PROGINS allele (n=651, OR=1.17, 95% CI=1.01-1.36, P=0.036). We also observed borderline evidence of an association between risk of endometrioid ovarian cancer and the +331C/T variant (n=725 cases; OR=0.80, 95% CI 0.62-1.04, P=0.100). These data suggest that while these three variants in the PGR are not associated with ovarian cancer overall, the PROGINS variant may play a modest role in risk of endometrioid ovarian cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Each panel shows the study-specific and summary odds ratios (boxes) and 95% confidence intervals (lines) for all cases and endometrioid subtype specific results for the three PGR SNPs. The size each box is proportionate to the number of subjects genotyped. See methods for full study names.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma.
    Le Page C, Köbel M, Meunier L, Provencher DM, Mes-Masson AM, Rahimi K. Le Page C, et al. J Pathol Clin Res. 2019 Jul;5(3):177-188. doi: 10.1002/cjp2.131. Epub 2019 Apr 20. J Pathol Clin Res. 2019. PMID: 30924313 Free PMC article.
  • Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.
    Babic A, Cramer DW, Kelemen LE, Köbel M, Steed H, Webb PM, Johnatty SE, deFazio A, Lambrechts D, Goodman MT, Heitz F, Matsuo K, Hosono S, Karlan BY, Jensen A, Kjær SK, Goode EL, Pejovic T, Moffitt M, Høgdall E, Høgdall C, McNeish I, Terry KL. Babic A, et al. Cancer Causes Control. 2017 May;28(5):459-468. doi: 10.1007/s10552-016-0841-3. Epub 2017 Jan 3. Cancer Causes Control. 2017. PMID: 28050675 Free PMC article.
  • Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer.
    Peedicayil A, Vierkant RA, Shridhar V, Schildkraut JM, Armasu S, Hartmann LC, Fridley BL, Cunningham JM, Phelan CM, Sellers TA, Goode EL. Peedicayil A, et al. Gynecol Oncol. 2009 Aug;114(2):260-4. doi: 10.1016/j.ygyno.2009.03.038. Epub 2009 May 5. Gynecol Oncol. 2009. PMID: 19419758 Free PMC article.
  • Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium.
    Johnatty SE, Beesley J, Chen X, Spurdle AB, Defazio A, Webb PM; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer); Goode EL, Rider DN, Vierkant RA, Anderson S, Wu AH, Pike M, Van Den Berg D, Moysich K, Ness R, Doherty J, Rossing MA, Pearce CL, Chenevix-Trench G. Johnatty SE, et al. Twin Res Hum Genet. 2009 Jun;12(3):269-75. doi: 10.1375/twin.12.3.269. Twin Res Hum Genet. 2009. PMID: 19456219 Free PMC article.
  • Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.
    Notaridou M, Quaye L, Dafou D, Jones C, Song H, Høgdall E, Kjaer SK, Christensen L, Høgdall C, Blaakaer J, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Gentry-Maharaj A, Wozniak E, Sher T, Jacobs IJ, Tyrer J, Schildkraut JM, Moorman PG, Iversen ES, Jakubowska A, Mędrek K, Lubiński J, Ness RB, Moysich KB, Lurie G, Wilkens LR, Carney ME, Wang-Gohrke S, Doherty JA, Rossing MA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Beesley J; Australian Ovarian Cancer Study Group/Australian Cancer Study (Ovarian Cancer); Gronwald J, Fasching PA, Chang-Claude J, Goodman MT, Chenevix-Trench G, Berchuck A, Pearce CL, Whittemore AS, Menon U, Pharoah PD, Gayther SA, Ramus SJ; Ovarian Cancer Association Consortium. Notaridou M, et al. Int J Cancer. 2011 May 1;128(9):2063-74. doi: 10.1002/ijc.25554. Int J Cancer. 2011. PMID: 20635389 Free PMC article.
See all "Cited by" articles

References

    1. Agoulnik IU, Tong XW, Fischer DC, Korner K, Atkinson NE, Edwards DP, Headon DR, Weigel NL, Kieback DG (2004) A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab 89: 6340–6347 - PubMed
    1. Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, Moriya T, Okamura K, Yajima A, Sasano H (2000) Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer 83: 1488–1494 - PMC - PubMed
    1. Auranen A, Song H, Waterfall C, Dicioccio RA, Kuschel B, Kjaer SK, Hogdall E, Hogdall C, Stratton J, Whittemore AS, Easton DF, Ponder BA, Novik KL, Dunning AM, Gayther S, Pharoah PD (2005) Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 117: 611–618 - PubMed
    1. Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G (2004) Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev 13: 2141–2147 - PubMed
    1. Cooper GS, Schildkraut JM, Whittemore AS, Marchbanks PA (1999) Pregnancy recency and risk of ovarian cancer. Cancer Causes Control 10: 397–402 - PubMed

Publication types

Substances